Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian T Tsuji

Showing results (41-50 of 103) with videos related to

Pageof 11
Sort By:
Antimicrobial Agents and Chemotherapy|November 29, 2017
Azithromycin Pharmacodynamics against Persistent Haemophilus influenzae in Chronic Obstructive Pulmonary DiseaseBrian T Tsuji, James Fisher, Raheal Boadi-Yeboah, et al.
Antimicrobial Agents and Chemotherapy|September 21, 2011
Predictors of agr dysfunction in methicillin-resistant Staphylococcus aureus (MRSA) isolates among patients with MRSA bloodstream infectionsJill M Butterfield, Brian T Tsuji, Jack Brown, et al.
The Journal of Antimicrobial Chemotherapy|November 18, 2017
Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection modelsCornelia B Landersdorfer, Jiping Wang, Veronika Wirth, et al.
The Journal of Antimicrobial Chemotherapy|August 14, 2016
Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable Pseudomonas aeruginosaVanessa E Rees, Jürgen B Bulitta, Antonio Oliver, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 7, 2011
Application of pharmacokinetic-pharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the deadBrian T Tsuji, Olanrewaju O Okusanya, Jurgen B Bulitta, et al.
Diagnostic Microbiology and Infectious Disease|April 26, 2011
Evaluation of the pharmacokinetics-pharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: implications for dose selectionOlanrewaju O Okusanya, Brian T Tsuji, Jurgen B Bülitta, et al.
Pharmacotherapy|December 1, 2010
Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosingLauren M Lim, Neang Ly, Dana Anderson, et al.
Antimicrobial Agents and Chemotherapy|August 31, 2011
Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inoculaPhillip J Bergen, Alan Forrest, Jürgen B Bulitta, et al.
Antimicrobial Agents and Chemotherapy|April 29, 2015
Emergence of polymyxin B resistance influences pathogenicity in Pseudomonas aeruginosa mutatorsZackery P Bulman, Mark D Sutton, Neang S Ly, et al.
The Journal of Antimicrobial Chemotherapy|June 12, 2012
Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutationsBrian T Tsuji, Jurgen B Bulitta, Tanya Brown, et al.
Pageof 11

Showing results (41-50 of 103) with videos related to

Sort By:
Pageof 11
Antimicrobial Agents and Chemotherapy|November 29, 2017
Azithromycin Pharmacodynamics against Persistent Haemophilus influenzae in Chronic Obstructive Pulmonary DiseaseBrian T Tsuji, James Fisher, Raheal Boadi-Yeboah, et al.
Antimicrobial Agents and Chemotherapy|September 21, 2011
Predictors of agr dysfunction in methicillin-resistant Staphylococcus aureus (MRSA) isolates among patients with MRSA bloodstream infectionsJill M Butterfield, Brian T Tsuji, Jack Brown, et al.
The Journal of Antimicrobial Chemotherapy|November 18, 2017
Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection modelsCornelia B Landersdorfer, Jiping Wang, Veronika Wirth, et al.
The Journal of Antimicrobial Chemotherapy|August 14, 2016
Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable Pseudomonas aeruginosaVanessa E Rees, Jürgen B Bulitta, Antonio Oliver, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 7, 2011
Application of pharmacokinetic-pharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the deadBrian T Tsuji, Olanrewaju O Okusanya, Jurgen B Bulitta, et al.
Diagnostic Microbiology and Infectious Disease|April 26, 2011
Evaluation of the pharmacokinetics-pharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: implications for dose selectionOlanrewaju O Okusanya, Brian T Tsuji, Jurgen B Bülitta, et al.
Pharmacotherapy|December 1, 2010
Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosingLauren M Lim, Neang Ly, Dana Anderson, et al.
Antimicrobial Agents and Chemotherapy|August 31, 2011
Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inoculaPhillip J Bergen, Alan Forrest, Jürgen B Bulitta, et al.
Antimicrobial Agents and Chemotherapy|April 29, 2015
Emergence of polymyxin B resistance influences pathogenicity in Pseudomonas aeruginosa mutatorsZackery P Bulman, Mark D Sutton, Neang S Ly, et al.
The Journal of Antimicrobial Chemotherapy|June 12, 2012
Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutationsBrian T Tsuji, Jurgen B Bulitta, Tanya Brown, et al.
Pageof 11